|
|
||||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
PHARMACOKINETICS AND PHARMACODYNAMICS |
From the Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, New York (S. A. Mousa, A. Aljada, S. Chaturvedi, M. Takieddin, H. Zhang); Departments of Chemical and Biological Engineering, Chemistry, and Chemical Biology and Biology, Rensselaer Polytechnic Institute, Troy, New York (F. Zhang, H. Zhang, L. Chi, R. J. Linhardt); and Emisphere, Inc, Tarrytown, New York (E. Arbit, M. C. Castelli, K. Friedman, M. M. Goldberg).
The present investigation determined the molecular structure and the pharmacokinetic and pharmacodynamic profiles of oral unfractionated heparin containing oral absorption enhancer sodium N-[8-(2-hydroxybenzoyl) amino]caprylate, salcaprozate sodium (SNAC) and assessed the safety and tolerability of the orally dosed heparin solid dosage form versus other routes. Sixteen healthy men were included in this single-dose, 3-way crossover, randomized, open-label study. Disaccharide compositional analysis was performed using capillary high-performance liquid chromatography with electrospray ionization mass spectrometry detection. The pharmacodynamics of heparin were obtained from analysis of plasma anti-factor Xa, anti-factor IIa, activated partial thromboplastin time, and total tissue factor pathway inhibitor data. The molecular weight properties and the disaccharide composition of orally administered unfractionated heparin/SNAC and parenterally administered unfractionated heparin are identical and consistent with the starting pharmaceutical standard heparin. Furthermore, the anti-factor Xa/anti-factor IIa ratio achieved is of approximately 1:1. This is the first true pharmacokinetic study to measure the chemical compositions of heparin administered by different routes.
Key Words: Oral heparin anticoagulants pharmacokinetics pharmacodynamics solid dosage form heparin composition
Address for correspondence: Shaker A. Mousa, Pharmaceutical Research Institute at Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208; e-mail: mousas{at}acp.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
![]() |
M. G. I. Riley and R. G. York Peri- and Postnatal Developmental Toxicity of Salcaprozate Sodium (SNAC) in Sprague-Dawley Rats International Journal of Toxicology, July 1, 2009; 28(4): 266 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. I. Riley, M. C. Castelli, and E. A. Paehler Subchronic Oral Toxicity of Salcaprozate Sodium (SNAC) in Sprague-Dawley and Wistar Rats International Journal of Toxicology, July 1, 2009; 28(4): 278 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. MacLean, A.-T. Casanova, L. Baselgia-Jeker, N. Neave, F. Larsen, L. Skillern, J. Drewe, and C. Beglinger Effect of Food on the Pharmacokinetics and Pharmacodynamics of an Oral Ghrelin Agonist (ARD-07) in Healthy Subjects J. Clin. Pharmacol., May 1, 2009; 49(5): 553 - 559. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |